ABSTRACT
Background This study tested the hypothesis that a combination of intra-articular injection of hyaluronic acid (HAi) and radial extracorporeal shock wave therapy (rESWT) is more effective than HAi alone in the treatment of symptomatic, primary focal osteochondral lesions of the patella (sPFOLP).
Methods We performed a retrospective analysis of n=81 subjects with unilateral sPFOLP who were treated with respectively HAi+rESWT (n=36) or HAi alone (n=45) at the outpatient department of our hospital between January 1st, 2014 and January 31th, 2018. Subjects in both cohorts also received education with special attention to reduction of going up and down the stairs, squatting and specific activities, as well as non-opioid analgesics if necessary. Efficacy was assessed using the pain visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, which were examined at baseline (BL) and six weeks (W6), three months (M3) and six months (M6) after BL, as well as during a last follow-up examination (LE) which was performed at 37.6 ± 1.7 (mean ± standard error of the mean) months after BL (range, 12-59 months). In addition, measurements of the area of the patellar bone marrow edema (PBME) on sagittal, fat suppression sequence magnetic resonance imaging (MRI) scans of the knee were performed at BL, M3, M6 and LE.
Results Subjects who were treated with HAi+rESWT showed significantly smaller mean VAS pain scores at W6, M3 and M6, significantly smaller mean WOMAC scores at W6, M3 and LE and significantly smaller mean PBME areas at M3, M6 and LE than subjects who were treated with HAi alone. No severe adverse events were observed.
Discussion The results of this study suggest that HAi+rESWT is safe and more effective than HAi alone in the treatment of sPFOLP. This result should be verified in adequate randomized controlled trials.
Level of evidence Level III; retrospective two-cohort study.
Competing Interest Statement
This study was performed with the radial extracorporeal shock wave device Swiss DolorClast, which is manufactured and distributed by Electro Medical Systems (Nyon, Switzerland). CS has received research funding at LMU Munich and consulted (until December 31st, 2017) for Electro Medical Systems. However, Electro Medical Systems had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All other authors declare no competing interests.
Funding Statement
This study did not receive any external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this retrospective study was granted by the Ethics Committee of the Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China (registration number KY201915). Because the study design did not require any additional interaction with the subjects there was no need to obtain consent for participation in this retrospective study according to the rules and regulations of Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and analyzed during this study are available from the corresponding author on reasonable request, taking into account any confidentiality.
Abbreviations
- BL
- baseline
- BMI
- body mass index
- EFD
- energy flux density
- EFD+
- positive energy flux density
- ESWT
- extracorporeal shock wave therapy
- F
- Fisher’s exact test
- fESWs
- focused extracorporeal shock waves
- fESWT
- focused extracorporeal shock wave therapy
- GLM-RM
- general linear model repeated measures
- HA
- hyaluronic acid
- HAi
- intra-articular injection of hyaluronic acid
- kg
- kilogram
- LE
- last follow-up examination
- M3
- three months after baseline
- m2
- squared meter
- M6
- six months after baseline
- max
- maximum value
- min
- minimum value
- mJ/mm2
- millijoule per squared millimeter
- ml
- milliliter
- MRI
- magnetic resonance imaging
- OA
- osteoarthritis
- PBME
- patellar bone marrow edema
- rESWs
- radial extracorporeal shock waves
- rESWT
- radial extracorporeal shock wave therapy
- RCT
- randomized controlled trial
- SD
- standard deviation
- SEM
- standard error of the mean
- sPFOLP
- symptomatic, primary focal osteochondral lesions of the patella
- T
- unpaired t test
- VAS
- visual analog scale
- W6
- six weeks
- WOMAC
- Western Ontario and McMaster Universities Osteoarthritis Index